My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Sanofi - American Depositary Shares (NQ:SNY)

48.20 -0.26 (-0.54%)

Streaming Delayed Price Updated: 1:28 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

39 40 Next >

Sanofi Raises Annual Guidance On Upbeat Q2 Performance ↗

July 28, 2022

Via Benzinga

A Monoclonal Antibody Treatment For ALS Could Begin Human Trials By 2023, According To Pasithea ↗

July 28, 2022

Pasithea Therapeutics Corp. (NASDAQ: KTTA), a biotech company looking for new treatments for psychiatric and neurological disorders, received an AU$1 million (US$694,000) gran

Via Benzinga

Earnings Scheduled For July 28, 2022 ↗

July 28, 2022

Companies Reporting Before The Bell • ArcelorMittal (NYSE:MT) is estimated to report earnings for its second quarter.

Via Benzinga

Daily Stock Analysis: Sanofi S.A. ↗

July 19, 2022

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. It was founded in 1973 and is headquartered in Paris.

Via Talk Markets

Earnings Outlook For Sanofi ↗

July 27, 2022

Sanofi (NASDAQ:SNY) is set to give its latest quarterly earnings report on Thursday, 2022-07-28. Here's what investors need to know before the announcement. Analysts estimate that Sanofi will report an...

Via Benzinga

Regeneron's Price Target Cut On Dim Prospects For Its Flagship Eye Product ↗

July 25, 2022

Via Benzinga

Amid RNA Setbacks, Start Up Bets On Sanofi's siRNA Platform ↗

July 25, 2022

Via Benzinga

Apple, Meta, Pfizer Among Key Companies Reporting In The Week Ahead, As Earning Picks Up Pace ↗

July 24, 2022

Big tech earnings will flow in thick and fast in the upcoming week, providing more clarity on how supply chain disruptions and the macroeconomic malaise have impacted these companies.

Via Benzinga

Sanofi's Fitusiran Prophylaxis Cuts Bleeds By 61% In Hemophilia Patients ↗

July 11, 2022

Via Benzinga

Sanofi Dives After FDA Slaps Its $3.7 Billion Drug With A Hold ↗

June 30, 2022

The company was testing the drug in multiple sclerosis and myasthenia gravis.

Via Investor's Business Daily

Why Sanofi Shares Are Falling Today ↗

June 30, 2022

Via Benzinga

Pasithea's Latest Drug Candidate Could Bring New Hope To ALS Patients Without Effective Treatment Options ↗

July 20, 2022

Amyotrophic lateral sclerosis (ALS) is a rare but painful and fatal disease that slowly shuts down all voluntary movements in the body, from walking to breathing.

Via Benzinga

Analyzing Sanofi's Short Interest ↗

July 19, 2022

Sanofi's (NASDAQ:SNY) short percent of float has fallen 14.29% since its last report. The company recently reported that it has 3.00 million shares sold short, which is 0.12% of...

Via Benzinga

Clovis Oncology (CLVS) Stock Pops 7% on Supply Agreement ↗

July 19, 2022

CLVS stock is rallying 7% after Clovis Oncology made a major deal with NorthStar Medical. Takeover speculation has swirled around Clovis.

Via InvestorPlace

The Daily Biotech Pulse: Sesen Bio Stops Lead Assest Development In US, FDA Approves Eton Pharma's Partial Seizures Drug, Bavarian Nordic Inks Multiple Supply Pact For Monkeypox Vaccine ↗

July 18, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures ↗

July 14, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Regeneron-Sanofi's Dupixent Hits Primary Goal In Esophagitis Patients Below 11 Years ↗

July 14, 2022

Via Benzinga

Sanofi Offloads 17 Products To Neuraxpharm ↗

July 13, 2022

Sanofi SA (NASDAQ: SNY) has entered a deal to hand over 17 products to central nervous system (CNS) specialist Neuraxpharm for an undisclosed sum.

Via Benzinga

The Daily Biotech Pulse: Europe Approves Second Round Of Booster Doses of mRNA COVID-19 Vaccines, Perrigo Seeks Approval For First OTC Birth Control Pill, MacroGenics Closes Head & Cancer Study After Patient Death ↗

July 11, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

SOBI-Sanofi Partnered Hemophilia Therapy Shows Superior Bleed Protection Than Prior Prophylaxis ↗

July 11, 2022

Via Benzinga

Biotech Stocks To Watch And Pharma Industry News ↗

July 08, 2022

Track the latest trends and leading stocks in the biotech and pharmaceutical industries.

Via Investor's Business Daily

This New York-Based Digital Therapeutics Company Looks To Disrupt a $475 Billion Market ↗

July 07, 2022

As the global coronavirus pandemic forced people to keep their distance from one another, there has been an increase in the adoption of digital health solutions among healthcare professionals and...

Via Benzinga

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Sanofi with Losses of $100,000 to Contact the Firm

July 05, 2022

From The Schall Law Firm

Via Business Wire

The Daily Biotech Pulse: AstraZeneca Goes Shopping, TYME Technologies & Syros Pharma Merger, FDA Clears Vertex Pharma's Stem Cell-Based Diabetes Therapy Study ↗

July 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Sanofi with Losses of $100,000 to Contact the Firm

July 01, 2022

From The Schall Law Firm

Via Business Wire

How Is The Market Feeling About Sanofi? ↗

July 01, 2022

Sanofi's (NASDAQ:SNY) short percent of float has fallen 22.22% since its last report. The company recently reported that it has 3.47 million shares sold short, which is 0.14% of...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates ↗

July 01, 2022

The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.

Via Benzinga

The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial ↗

June 30, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Pfizer, Moderna Analysts Respond To FDA COVID Booster Ruling: 'Revenues Will Decline' ↗

June 29, 2022

The Food and Drug Administration’s panel of independent vaccine experts recently voted 19 to 2 to recommend a new batch of COVID-19 booster shots targeting the omicron variant this fall. The news,...

Via Benzinga

Sanofi Lowers Out-Of-Pocket Insulin Cost For Uninsured Patients ↗

June 29, 2022

Via Benzinga

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

39 40 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.